Studies have shown that the vaccine is not as effective as competing products from Biontech / Pfizer and Moderna.
(Photo: Reuters)
Frankfurt A good three months after the submission of weak test results for its Covid vaccine, Tübingen-based Curevac is facing a difficult realignment. The company announced on Tuesday that it would withdraw its mRNA-based vaccine candidate “CVnCoV” from the ongoing approval process with the European Medicines Agency (Ema).
Instead, Curevac wants to focus its resources more on an improved successor product and its alliance with the British pharmaceutical giant Glaxo-Smithkline (GSK). Both the advance delivery contract with the EU and the partnership with Bayer for the distribution of the vaccine are no longer valid.
The biotech company is also turning around in terms of technology: they want to continue working on vaccines based on unmodified mRNA. At the same time, work on vaccines made from modified mRNA will be stepped up together with GSK. Curevac and GSK are thus turning to the mRNA technology on which the successful Covid vaccines from Biontech / Pfizer and Moderna are based.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further